Diabetes and Endocrinology

Host: Scott Kahan, MD, MPH
Guest: Ken Fujioka, MD
Guest: Carol Wysham, MD

Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management.

Host: John Buse, MD, PhD
Guest: Mary de Groot, PhD

The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Host: Stuart Weinzimer, MD

The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients’ quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD

From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: John Buse, MD, PhD
Guest: Michael Fang, PhD

According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study’s key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.

Host: John Buse, MD, PhD
Guest: Maria Jose Redondo, MD, PhD, MPH

A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Host: John Buse, MD, PhD
Guest: Helen Murphy, PhD

There are many challenges associated with managing type 1 diabetes (T1D) in pregnant patients, which is why a recent study examined the use of an automated insulin delivery system in this patient population. Using this method, insulin doses were adjusted every 8 to 10 minutes according to a patient’s real-time glucose levels taken from her continuous glucose monitor. As a result, women experienced a higher percentage time in the pregnancy glucose target range, less hyperglycemia, and less gestational weight gain. Learn more about how these findings may impact the management of T1D both during and after pregnancy with Dr. John Buse and Dr. Helen Murphy, a Professor of Medicine in Diabetes and Antenatal Care at the University of East Anglia in the United Kingdom.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: David Selzer, MD

New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Host: John Buse, MD, PhD
Guest: Beth Pyatak, PhD, OTR/L

According to a recent study, fluncuations in glucose levels while sleeping can directly impact type 1 diabetes patients’ ability to complete daily activities. In fact, it was found that higher variability overnight led to lower sustained attention and lower engagement in demanding activities the following day. So how can we control glucose levels to help our patients feel better? Explore the study’s key findings and management strategies with Dr. John Buse and Dr. Elizabeth Pyatak, an Associate Professor of Occupational Science and Occupational Therapy at the University of Southern California who worked on the study.

Host: John Buse, MD, PhD
Guest: Simon Heller, MD

Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they’ll review Dr. Heller’s recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.

Host: John Buse, MD, PhD
Guest: Jean-Philippe Drouin-Chartier, DtP, PhD

What’s the relationship between ultra-processed food consumption and the risk of developing type 2 diabetes? Find out with Dr. John Buse as he speaks with Dr. Jean-Philippe Drouin-Chartier about his research that sought to answer this exact question. Dr. Drouin-Chartier is an Assistant Professor at the Faculté de Pharmacie at Laval University and a researcher in the Nutrition, Health, and Society Center of the Institute on Nutrition and Functional Foods in Quebec, Canada.

Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Maria Luiza Caramori, MD, PhD, MSc
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC

Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.

Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael Charlton, MD

Liver disease is highly prevalent in patients with type 2 diabetes, and it’s much more likely to be a clinically significant issue in these patients as well. So it’s important to evaluate patients for liver disease during routine check-ups. Dive further into the effects of liver disease in diabetic care with Dr. Peter Buch as he speaks with Dr. Michael Charlton, Professor of Medicine and Co-Director of the Transplant Institute at the University of Chicago.

Host: John Buse, MD, PhD
Guest: David Cherney, MD, PhD

There have been several major advances regarding the management of chronic kidney disease in patients with type 2 diabetes over the last 5 years, leading Dr. David Cherney and a team of authors to publish a narrative review on how to best manage these patients using the latest treatment options like SGLT2 inhibitors and non-steroidal MRAs. Tune in to hear him share key highlights from the review with Dr. John Buse. Dr. Cherney is a Professor of Medicine at the University of Toronto and the Director of the Renal Physiology Laboratory at University Health Network in Canada.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD, MBA, MPH

There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.

Host: John Buse, MD, PhD
Guest: Louis Philipson, MD, PhD

Over the last 15 years, the monogenic diabetes registry now has over 4,000 patients involved, and from that, the RADIANT study was started to identify new kinds of rare and atypical diabetes. So how can genetics testing and the RADIANT study provide atypical diabetes patients with better diagnoses and treatment? Learn more with Dr. John Buse and Dr. Louis Philipson, Professor in the Department of Medicine and Pediatrics at the University of Chicago.

Host: John Buse, MD, PhD
Guest: David Simmons, MD

Gestational hypertension is more common in preeclampsia, and there’s more chance of the baby ending up in the neonatal intensive care unit. So what can we learn from the randomized trials of women patients with gestational diabetes? Learn more with Dr. John Buse as he speaks with Dr. David Simmons, Distinguished Professor of Medicine at the Western Sydney University Macarthur Clinical School in Australia.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD

We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.

Host: John Buse, MD, PhD
Guest: Karen D. Corbin, PhD, RD

One of the biggest missing links in current literature about obesity and the gut microbiome was causality. In an effort to address that gap, a recent clinical trial was conducted, and now, the results are in. So what were the key findings, and how can we translate those findings into clinical practice? Find out how one’s diet can affect the gut microbiome with Dr. John Buse and Dr. Karen Corbin, an Investigator at the AdventHealth Translational Research Institute in Orlando, Florida.